Well-positioned in the plasma industry, Grifols could be a winner from the ongoing pandemic crisis — as the Spanish pharma giant has joined forces with the US to develop a COVID-19 treatment. The group’s resilient business — operating in an oligopolistic market, with high demand and significant barriers to entry — translating into strong potential for top-line growth and improving margins, along with a robust R&D pipeline, supports the investment case at current le
26 Mar 2020
Potential COVID-19 treatment in the lab
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Potential COVID-19 treatment in the lab
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
26 Mar 2020 -
Author:
Rishabh Kochar -
Pages:
2
Well-positioned in the plasma industry, Grifols could be a winner from the ongoing pandemic crisis — as the Spanish pharma giant has joined forces with the US to develop a COVID-19 treatment. The group’s resilient business — operating in an oligopolistic market, with high demand and significant barriers to entry — translating into strong potential for top-line growth and improving margins, along with a robust R&D pipeline, supports the investment case at current le